Dr. Jessica Paulus explores opportunities and challenges with using RWD in conducting comparative effectiveness research.
Real-world data (RWD) can provide valuable insights into treatment effectiveness and be used to generate evidence for decision making. Understanding which data, when and how to use it, and special considerations when leveraging for regulatory and other stakeholders are all critical to success for RWD comparative effectiveness research (CER). Dr. Jessica Paulus explores opportunities and challenges with using RWD in conducting CER, including; methods to reduce bias, regulatory considerations, and examples of large real-world datasets and use case applications.
Key Topics Include:
- Explore opportunities and challenges in conducting CER using RWD, including methods to reduce bias
- Identify examples of using large real-world datasets to generate comparative effectiveness insights
- Understand regulatory considerations when using RWD for comparative effectiveness
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Presenters
Senior Director
Research/Epidemiology
OM1 Inc.
Jess Paulus, ScD is the Senior Director of Epidemiology at OM1. She received her doctorate in Epidemiology from Harvard T.H. Chan School of Public Health and holds an adjunct appointment at Tufts University School of Medicine. She leads a team of epidemiologists at OM1 to leverage real world data to inform clinical and regulatory decision making.
Production Partner
OM1
With specialization in chronic conditions, OM1 leverages its extensive, specialty clinical networks and an artificial intelligence (AI) platform to offer enriched health care datasets, research analytics, data modeling, decision support, and retrospective and prospective clinical studies.
Additional Content From OM1
Cutting Edge Conversations: Addressing COVID-19 During Uncertainty
Hayley Crawford, PhD, and Carl Marci, MD, discuss how their specific industries have developed new innovations in response to the COVID-19 pandemic.
Cutting Edge Conversations: Addressing Orphan and Rare Diseases
Joseph Zabinski, PhD, MEM, and Jonathan Kish, PhD, MPH, discuss how research groups are working in the realm of orphan and rare diseases.
Additional Content From HealthEconomics.Com
Health Economic and Outcome Research (HEOR) for Medical Technologies for the US Healthcare Systems
Deepak Sahu, MBA, explains how HEOR studies are important for generating useful effectiveness data for success of medical technologies.
Designing Causal Inference Studies Using Real-World Data
In this webinar, experts provide an overview of causal inference, along with step-by-step guidance to designing these studies using real-world healthcare data.
Social Media Data: Opportunities and Insights for Clinical Research
Hear four experts from ICON and Kap Code provide insights on how to collect, use, analyze, and interpret social media data in different contexts. These experts share knowledge from over fifteen years of successfully developing and adapting algorithms to treat this kind of data.
Related Content
Streamlining Health Technology Assessments by Automating Literature Reviews
Experts provide a deep dive into what Health Technology Assessment (HTA) agencies do and the types of literature reviews they do.
Achieving Consensus When Everyone is an Expert, but No One Agrees
Watch experts from PHAR, Novartis, and Bausch Health discuss the Delphi panels and how the results are used.
Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access
Experts present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.